Zhang, Yingzhen N.
Fowler, Kathryn J.
Boehringer, Andrew S.
Montes, Vivian
Schlein, Alexandra N.
Covarrubias, Yesenia
Wolfson, Tanya
Hong, Cheng W.
Valasek, Mark A.
Andre, Michael P.
Loomba, Rohit
Sirlin, Claude B. http://orcid.org/0000-0002-6639-9072
Article History
Received: 17 March 2021
Revised: 7 September 2021
Accepted: 9 October 2021
First Online: 2 December 2021
Declarations
:
: The scientific guarantor of this publication is Dr. Claude B. Sirlin.
: The authors of this manuscript declare relationships with the following companies, for which the authors engaged in activities not related to the present article: RL serves as a consultant or advisory board member for Arrowhead Pharmaceuticals, AstraZeneca, Bird Rock Bio, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Cirius, CohBar, Conatus, Eli Lilly, Galmed, Gemphire, Gilead, Glympse bio, GNI, GRI Bio, Intercept, Ionis, Janssen, Merck, Metacrine, NGM Biopharmaceuticals, Novartis, Novo Nordisk, Pfizer, Prometheus, Sanofi, Siemens, and Viking Therapeutics. CBS is on the advisory boards of AMRA, Guerbet, and VirtualScopics; is a consultant for GE Healthcare, Bayer, Boehringer Ingelheim, AMRA, and Fulcrum; institution received grants from Gilead, GE Healthcare, Siemens, GE MRI, Bayer, GE Digital, GE Ultrasound, ACR Innovation, and Philips; served on the speakers bureau for GE Healthcare; developed educational presentations for Medscape and Resoundant; institution has lab service agreements with Enanta, ICON, Gilead, Shire, VirtualScopics, Intercept, Synageva, Takeda, Genzyme, Janssen, and NuSirt.
: Tanya Wolfson, MA, kindly provided statistical advice for this manuscript and is one of the authors.
: Written informed consent was obtained from all patients in this study.
: Institutional Review Board approval was obtained.
: •Cross-sectional study